Changes in Hong Kong stocks | Kingsley Biotech (01548) rose nearly 9% Overseas Twist has received order verification, AI demand has begun to contribute to business growth

The Zhitong Finance App learned that Kingsley Biotech (01548) rose nearly 9%. As of press release, it had risen 8.94% to HK$26.32, with a turnover of HK$827 million.

According to the news, US DNA synthesis company Twist recently released its third fiscal quarter report: achieved revenue of US$118 million, an increase of 23% over the previous year, and achieved growth for the 14th consecutive quarter. Emily LeProust, CEO and co-founder of Twist, said during the earnings call that the company's demand for DNA synthesis, protein solutions, and next-generation sequencing businesses have jointly driven performance growth, and AI drug development is becoming an important driving force for growth. According to China Post Securities, AI pharmaceuticals continue to advance, TWST high growth verifies that DBTL closes the loop, and focuses on opportunities for industrial chain growth.

Guolian Minsheng Securities believes that Kingsley has expanded from a gene synthesis leader to a “gene to protein” integrated verification platform, and AI demand has begun to contribute to business growth. AI-driven drug development and multi-antibody drug development demand are growing rapidly, driving rapid growth in the gene-to-protein business; in 2025, the life science business group's revenue was $522 million, an increase of 14.8% over the previous year, while continuing to expand automated and digital production capabilities. Revenue from integrated protein expression services increased by about 50% year on year in 2025, and orders for transfer from gene synthesis to protein expression platforms increased 160% year over year.